MRM Health, established in the Ghent biotech cluster, develops innovative human microbiome-based medicines.
Included in the AvH investment portfolio since 2020.
16.92 %
Related participations
Growth Capital
Confo Therapeutics
Confo's mission is to develop novel GPCR modulators for patients with severe and underserved diseases, with a current emphasis on rare diseases, peripheral pain and obesity.
Growth Capital
DISCO Pharmaceuticals
DISCO Pharmaceuticals uses groundbreaking proteomics technology to map the cancer cell surfaceome. DISCO Pharmaceuticals has pioneered the initial surfaceome mapping for Small Cell Lung Cancer (SCLC) and Colorectal Cancer (CRC). The company is currently advancing multiple ADC candidates toward studies that will enable submission for Investigational New Drug (IND) status.
Growth Capital
OncoDNA
OncoDNA supports cancer specialists by providing comprehensive characterization of a patient’s cancer.